Noul, an artificial intelligence (AI)-based blood and cancer diagnostic specialist, announced on Aug. 25 that it has signed a contract to supply its AI-based malaria diagnostic solution miLab MAL to Ghana, West Africa, for a total of $975,000 (approximately 1.36 billion won) over two years.

This contract is another testament to the performance and reliability of miLab MAL, based on accumulated performance evaluations and supply experience in major African markets including Benin, Nigeria, Côte d’Ivoire, and Angola. Noul plans to gradually supply the AI malaria diagnostic solution to major health institutions and malaria management hubs in Ghana through local partners.
Noul’s miLab MAL demonstrated superior performance compared to standard microscopy, recording 100% sensitivity, specificity, and positive and negative predictive values in joint research with Labcorp, the largest diagnostic lab chain in the United States.

The World Health Organization (WHO) subsidiary International Drug Purchase Facility (UNITAID) report also introduced it as “the most advanced form of digital microscopy platform integrating all functions of microscopic diagnosis,” drawing attention in the global malaria diagnosis field for its unparalleled performance.

Notably, as the only medical AI company invited to a meeting with the visiting chairman of the Gates Foundation, Noul has been recognized for its technological innovation and growth potential in solving global health challenges.

Lim Chan-yang, CEO of Noul, said, “The demand for miLab MAL is steadily expanding through public procurement and various partnerships in West Africa, which accounts for one-third of global malaria cases, increasing our growth momentum.” He added, “Having firmly established our position in the African market, we will continue to accelerate expansion into the global market including Europe and the United States, and consistently implement value-up strategies.”